Promotional feature
Exciting new research into the long-term safety and efficacy of Arthrosamid®, an intra-articular 2.5% polyacrylamide hydrogel (iPAAG), has recently been unveiled at the 25th World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases in Rome.
Backed by over two decades of research1, Arthrosamid® is a hydrogel injectable treatment developed by Contura Orthopaedics Ltd. As a non-biodegradable, non-surgical, single-injection, it has become an alternative to conventional therapies for knee osteoarthritis (OA), offering long-lasting relief from chronic joint pain.
During the congress, researcher Professor Henning Bliddal presented the latest findings from the ongoing “IDA” study, an extended prospective open-label clinical trial. This latest data shows that single injections of 6 ml intra-articular iPAAG are well tolerated and continued to provide clinically important effectiveness at 5-years after treatment.2 The prospective multicentre study (3 sites in Denmark) involved 49 participants (31 females) with an average age of 70 (range 44 – 86 years) with moderate to severe knee OA. For patients, these latest results mean that the benefits of the treatment including pain relief and improved mobility can be experienced up to five years post treatment – allowing people to “Move freely, live fully”.
The study, titled “Polyacrylamide Hydrogel for Knee Osteoarthritis: 5-Year Results from a Prospective Study”, was co-authored by H. Bliddal, J. Beier, A. Hartkopp, P. Conaghan, and M. Henriksen, and adds to the growing portfolio of evidence demonstrating Arthrosamid®’s long-term efficacy.
Prof. Bliddal also presented new 10-year safety data3, reinforcing the favourable risk profile of iPAAG for intra-articular use. The study, “10-Year Follow-Up After Intra-Articular Injections of 2.5% Polyacrylamide Hydrogel for Knee Osteoarthritis”, demonstrated very few reported adverse events over a decade, with very few patients recalling pain or problems post-injection. Surgical records from subsequent knee replacements gave no indications of unusual adverse reactions.
Initially used in veterinary medicine to treat joint issues in horses, Arthrosamid® has transitioned into human orthopaedics with resounding success. In just under three years, over 15,000 patients across Europe and globally have received treatment—testament to both clinician confidence and patient demand for a non-surgical alternative in the care and treatment of knee OA. Unlike traditional OA injections, Arthrosamid® integrates into the synovial tissue of the knee4, helping to reduce pain with a single-dose, without surgery.
With around 5.4 million people in the UK alone affected by knee OA5, Arthrosamid® represents a significant advancement in the current care pathway for managing knee OA, potentially delaying or even avoiding the need for total knee replacement surgery.
Rakesh Tailor, CEO of the Contura Group, comments: “This 5-year data point is an incredible milestone for the company and for our patient population. We’re thrilled that Prof. Bliddal and the team are able to share these results, showing not only a reassuring safety profile, but also demonstrating sustained pain reduction and lasting improved function with benefits now seen five years after the initial single injection.”
“We have always believed Arthrosamid® to be a game-changer in OA treatment. With few innovations in this space over recent decades, this latest data further strengthens our confidence in Arthrosamid’s potential to redefine the treatment of knee OA and bolsters our resolve to make it more accessible as a treatment option through our expanding network of healthcare professionals worldwide.”
For more information, visit: www.arthrosamid.com
References:
- Data on file
- Bliddal, H., et al. (2025) A Prospective Study of Polyacrylamide Hydrogel Injection for Knee Osteoarthritis: Results From 5 Years After Treatment. Presented at WCO-IOF-ESCEO 2025.4. Bliddal, H., et al. (2024) Polyacrylamide hydrogel for knee osteoarthritis: Four-year results from a prospective study. Orthop Procs. 2024;106-B(SUPP_18):106.
- Bliddal,H.., et al. (2025) 10-Year Follow-Up After Intra-Articular Injections of 2.5% Polyacrylamide Hydrogel for Knee Osteoarthritis. Presented at WCO-IOF-ESCEO 2025.
- Christensen, L., et al. (2016). Histological Appearance of the Synovial Membrane after Treatment of Knee Osteoarthritis with Polyacrylamide Gel Injections: A Case Report. Journal of Arthritis. Vol 5: 217.
- Versus Arthritis, 2023
Source: Contura Group
Image: Arthrosmid
